Effect of Carbohydrate Consumption on Fatigue and Muscle Damage in Jiu-Jitsu Athletes

January 15, 2019 updated by: Cláudia Dornelles Schneider, Federal University of Health Science of Porto Alegre

Effect of Carbohydrate Consumption on Fatigue and Muscle Damage in Jiu-Jitsu Athletes: A Randomized Clinical Trial

The study is a randomized, double-blinded, placebo-controlled trial that will include the participation of 14 Jiu-Jitsu athletes between 18 and 33 years. The aim of the study is to evaluate the effects of carbohydrate consumption on fatigue and exercise-induced muscle damage in Jiu-Jitsu athletes.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Brazilian Jiu-Jitsu (BJJ) is a sport characterized by intermittent high-intensity efforts separated by periods of low intensity. Muscular strength is considered one of the most important physical components to be developed, especially in the upper limbs through dynamic and static actions. The activities of high intensity (relation effort-pause) carried out by the upper and lower limbs during BJJ can induce muscle fatigue. In order to minimize the glycogen depletion and to guarantee the availability of energy substrate to the athlete during the physical exercise, the carbohydrate intake before moderate intensity exercises should be between 5-7 g / kg of weight / day. The intervention group will receive a 30g maltodextrin beverage and the placebo group a non-carbohydrate drink. There will be 3 combat simulations of 8 min each, with intervals of 10 min between fights. Athletes will be instructed to remain with their usual intake during the study. The outcomes will be: manual grip strength (dynamometer), upper limb strength (KGST), lower limb strength (vertical jump), subjective exertion perception (Borg scale), pain perception (Nilsson scale), blood markers of muscle damage (CK and LDH), lactate, and glycemia.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
14

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • Rio Grande Do Sul
      • Pôrto Alegre, Rio Grande Do Sul, Brazil, 90050170
        • Gabriella B. Möller

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 33 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Compete in the categories of weight between 70kg and 88,3kg (weight classification from light to medium heavy, belonging to the bands purple to brown).
  • Age between 18 and 33 years.
  • Be training at least three times a week, minimum of 1,5 hours per day, for at least 3 consecutive months.
  • Have not used anabolic steroids in the last 6 months during the study period.
  • Do not use any type of dietary supplement in the last 3 months.
  • Self-declared healthy individuals.

Exclusion Criteria:

  • Recent muscle injury (within the last 3 months) that compromises and / or impedes the performance of the exercise requested in the study.
  • Be in a time of rapid weight loss (pre-competition).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Carbohydrate
30g of carbohydrate (maltodextrin) diluted in 300ml of water. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
Dietary supplement: Carbohydrate (maltodextrin)
maltodextrin flavored
Placebo Comparator: Placebo
300 ml of a non-caloric drink. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
Other: Placebo
non-caloric drink

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
change in upper limbs strength
Time Frame: Pre-exercise; at 2 intervals during exercise; 24hour and 48hour after exercise
Kimono Grip Strength Test
Pre-exercise; at 2 intervals during exercise; 24hour and 48hour after exercise

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
change in lower limbs power
Time Frame: Pre-exercise; at 2 intervals during exercise; 24hour and 48hour after exercise
Horizontal Countermovement Jump
Pre-exercise; at 2 intervals during exercise; 24hour and 48hour after exercise
change in hand grip strength
Time Frame: Pre-exercise; at 2 intervals during exercise; 24hour and 48hour after exercise
Grip Strength Test
Pre-exercise; at 2 intervals during exercise; 24hour and 48hour after exercise
change in creatine kinase
Time Frame: Pre-exercise; immediatly post-exercise; 24hour and 48hour after exercise
3 ml of blood samples
Pre-exercise; immediatly post-exercise; 24hour and 48hour after exercise
change in glucose
Time Frame: Pre-exercise; at 2 intervals during exercise; immediatly post-exercise
fingertip blood measured by Accutrend® Active glucose-specific reagent tape
Pre-exercise; at 2 intervals during exercise; immediatly post-exercise
change in lactate
Time Frame: At 2 intervals during exercise; immediatly post-exercise
fingertip blood measured by Accutrend Plus.
At 2 intervals during exercise; immediatly post-exercise
change in lactate dehydrogenase
Time Frame: Pre-exercise; immediatly post-exercise; 24hour and 48hour after exercise
3 ml of blood samples
Pre-exercise; immediatly post-exercise; 24hour and 48hour after exercise

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Federal University of Health Science of Porto Alegre

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Claudia D Schneider, PhD, Federal University of Health Science of Porto Alegre

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 26, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2017

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2017

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 26, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 28, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 29, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 16, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 15, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 1.873.861

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fatigue

Clinical Trials on Carbohydrate (maltodextrin)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings